[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457774":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":38,"responsibleParty":53,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"China Medical University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NMDAE plus Anti-inflammatory Agent (AIFA)","EXPERIMENTAL","An NMDA enhancer plus a drug with anti-inflammatory property",[13],"Drug: NMDAE plus AIFA",{"label":15,"type":16,"description":17,"interventionNames":18},"NMDAE plus Placebo","PLACEBO_COMPARATOR","An NMDA enhancer plus Placebo",[19],"Drug: NMDAE plus Placebo Cap",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","NMDAE plus AIFA","Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"NMDAE plus Placebo Cap","Use of an NMDA enhancer plus placebo as a comparator",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Hsien-Yuan Lane, M.D., Ph.D","CONTACT","886 4 22052121","1855","hylane@gmail.com",[39],{"facility":40,"status":41,"city":42,"state":26,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Department of Psychiatry, China Medical University Hospital","RECRUITING","Taichung","Taiwan","TW",{"type":46,"coordinates":47},"Point",[48,49],120.6839,24.1469,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[56],{"name":57,"class":6},"National Health Research Institutes, Taiwan","100457774","phase-2-combination-of-nmda-enhancing-and-anti-inflammatory-treatments-for-ultra-resistant-schizophrenia-100457774",false,"NCT05240976","Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia","Inclusion Criteria:\n\n* Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia\n* Are treatment-resistant to standard treatments of at least two specific antipsychotics before clozapine treatment\n* Are receiving adequate trials of clozapine for more than 12 weeks but without satisfactory response\n* PANSS total score ≥ 70; SANS total score ≥ 40\n* Have sufficient education to communicate effectively and are capable of completing the assessments of the study\n* Agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder\n* History of epilepsy, head trauma, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study\n* Clinically significant laboratory screening tests (including blood routine, biochemical tests)\n* Pregnancy or lactation\n* Inability to follow protocol","ALL","18 Years","65 Years",{"count":68,"type":69},80,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine for clinical symptoms but not cognitive function in the treatment of ultra-resistant schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of ultra-resistant schizophrenia remains unknown.",[75],"Schizophrenia",[77,78,79],"Ultra-resistant schizophrenia","NMDA","Inflammation","2026-03-21",{"date":82,"type":83},"2026-03-24","ACTUAL",{"date":85,"type":83},"2022-02-23",{"date":87,"type":69},"2027-03",{"name":5,"class":6},1]